Neuro-oncology
From the Journals
Can Addressing Depression Reduce Chemo Toxicity in Older Adults?
Researchers evaluated whether greater reductions in grade 3 chemotherapy-related toxicities occurred with geriatric assessment-driven...
News from the FDA/CDC
FDA Approves First Targeted Therapy for Gliomas With IDH Mutations
The approval of vorasidenib marks “one of the biggest advances in low-grade glioma in more than two decades.”
News from the FDA/CDC
FDA Approves First Engineered Cell Therapy for a Solid Tumor
This T-cell receptor therapy modifies existing receptors to recognize an array of antigens on the surface of cancer cells.
From the Journals
The Last 30 Days: How Oncologists’ Choices Affect End-of-Life Cancer Care
Researchers analyze data from more than 17,000 patients who died of cancer between 2012 and 2017.
From the Journals
Ancient Viruses in Our DNA Hold Clues to Cancer Treatment
Targeting remnants of a virus in our DNA could lead to more effective cancer treatment with fewer side effects.
Feature
Greater Transparency of Oncologists’ Pharma Relationships Needed
Reducing industry payments to hematologists and oncologists could benefit patients, say experts.
From the Journals
Should Cancer Trial Eligibility Become More Inclusive?
A new study highlights the potential benefits of broadening eligibility criteria for clinical trials.
From the Journals
Weight Loss Drugs Cut Cancer Risk in Diabetes Patients
Researchers examine electronic health records of patients who had type 2 diabetes, no prior diagnosis of obesity-related cancers, and had been...
From the Journals
Urticaria Linked to Higher Cancer Risk, Study Finds
Researchers compare the incident cancer risk between patients with urticaria and the general population using data from Danish healthcare...
Feature
Time Warp: Fax Machines Still Common in Oncology Practice. Why?
Oncologists are among the many specialists across the country at the mercy of telecopiers.
Feature
Cancer Drug Shortages Continue in the US, Survey Finds
Not having enough of a significant spectrum of generic chemotherapies and supportive care medications is an ongoing issue, NCCN surveys suggest....